Pfizer Halts Late-Stage Lung Cancer Drug Trial

by: cancercompass

For safety reasons, Pfizer has stopped patient enrollment for a late-stage lung cancer trial of its experimental drug, figitumumab, reports Reuters.

The company said independent safety monitors recommended halting the study after deaths occurred in patients taking figitumumab.

Patients currently enrolled in the study may continue their treatment in consultation with their physicians. As of 9/30/2009, 681 patients were enrolled in the Phase 3 study out of a target of 820, reports the company.

Clinical trial investigators and regulatory agencies were notified; they will work closely with the safety monitoring committee on analyzing the date before issuing further guidance.